Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 20Gastrointestinal 5Lymphoid 3Genitourinary 3Gynecologic 2Dermatologic 2CNS 2Breast 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Endocrine 1

Conditions

Melanoma 43Colorectal Neoplasms 8Uveal Melanoma 5Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Stomach Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Lung Neoplasms 3Carcinoma, Merkel Cell 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Pancreatic Neoplasms 2Glioblastoma 2Carcinoma, Hepatocellular 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parotid Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1

Interventions

Cyclophosphamide 16pembrolizumab 14Radiosurgery 7Nivolumab 5Celecoxib 5poly ICLC 4Radiation 4Injections 4Radiotherapy 3Melphalan 3Ipilimumab 3Filgrastim 3Etoposide 3Docetaxel 3Cryosurgery 3Blood Specimen Collection 3Biopsy 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2tislelizumab 2talimogene laherparepvec 2spartalizumab 2fludarabine phosphate 2fludarabine 2durvalumab 2cemiplimab 2atezolizumab 2aldesleukin 2Transurethral Resection of Prostate 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma × Bevacizumab × Dermatologic × Clear all
NCT05075993 2025-12-26

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
352 enrolled
DermatologicGastrointestinalGynecologicSarcoma

Uveal Melanoma, Carcinoma, Hepatocellular, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

GI Innovation, Inc.

Phase 1/2 Recruiting
358 enrolled
DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡